Burkitt lymphoma is caused by a genetic error that forces a growth-promoting gene called MYC into overdrive, triggering extremely rapid multiplication of a type of white blood cell. This core genetic defect is present in every case, but what triggers it varies depending on geography, viral exposure, and immune status. Three distinct forms of the disease exist, each with different contributing causes, though they all share the same underlying mechanism.
The MYC Translocation: The Central Defect
Every case of Burkitt lymphoma involves a chromosomal swap called a translocation. A piece of chromosome 8, carrying the MYC gene, breaks off and attaches to chromosome 14, landing next to genes that control antibody production. Because antibody genes are among the most active in immune cells, MYC suddenly falls under their control and gets switched on permanently. The result is a B cell (a type of immune cell) that divides at an extraordinary rate, with nearly 100% of tumor cells actively replicating at any given time.
This translocation doesn’t happen randomly. It occurs during normal immune cell development, when B cells are rearranging their DNA to build unique antibodies. The molecular machinery that cuts and reassembles antibody gene segments occasionally makes a mistake, joining MYC to an antibody gene instead. In endemic cases (those linked to malaria-endemic regions), the error typically happens during an early stage of antibody gene assembly. In sporadic cases seen in higher-income countries, it tends to occur during a later process called class switching, when mature B cells change the type of antibody they produce.
Supporting Mutations That Compound the Problem
MYC activation alone isn’t always enough. Additional mutations in genes called ID3 and TCF3 have been identified as molecular hallmarks of Burkitt lymphoma. Normally, ID3 acts as a brake on TCF3, a protein that promotes B-cell survival and growth signaling. When ID3 is damaged by mutation, it can no longer restrain TCF3, so the cell receives a constant “survive and grow” signal on top of the MYC-driven proliferation. These ID3 mutations appear in both endemic and sporadic forms of the disease, suggesting they play a fundamental role regardless of what initially triggers the MYC translocation.
Epstein-Barr Virus and Its Role
Epstein-Barr virus (EBV), the same virus that causes mono, is present in about 95% of endemic Burkitt lymphoma cases. Its role is more subtle than simply infecting a cell and turning it cancerous. EBV appears to suppress the natural self-destruct mechanism that damaged B cells would normally activate, allowing cells with dangerous genetic errors to survive instead of dying off. EBV-positive tumors also show higher activity of an enzyme called AID, which is responsible for making targeted cuts in B-cell DNA during normal antibody diversification. When AID is overactive, it introduces mutations across the genome beyond where it’s supposed to work, increasing the overall mutational burden and raising the odds of hitting a critical gene.
In sporadic Burkitt lymphoma, which occurs mainly in North America and Europe, EBV is found in only 10 to 30% of cases, mostly in patients over age 50. This tells us EBV isn’t strictly required for the disease to develop, but it significantly raises the risk when present, particularly in combination with other environmental factors.
Malaria as a Co-Factor in Endemic Regions
The geographic pattern of endemic Burkitt lymphoma closely tracks malaria transmission, concentrated in a band across sub-Saharan Africa sometimes called the “Burkitt Lymphoma Belt.” Chronic, repeated malaria infection acts as a powerful co-factor alongside EBV. Research from the EMBLEM study in East Africa found that for every 100 estimated malaria infections a child accumulates, the risk of endemic Burkitt lymphoma increases by 39%. That number of infections may sound extreme, but among 10-year-olds in high-transmission areas, cumulative infection counts ranged from 4 to 315.
Malaria’s contribution appears to work through the same AID enzyme that EBV amplifies. The malaria parasite, Plasmodium falciparum, causes sustained, abnormal activation of AID in B cells, both directly and through indirect immune stimulation. When malaria and EBV are both present, they synergize to keep AID expression elevated for prolonged periods, dramatically increasing the chance of the chromosome 8-to-14 translocation that defines the disease. The highest risk falls on children between ages 5 and 11 who have experienced hundreds of repeated infections.
HIV and Immunodeficiency-Associated Cases
People living with HIV face a 50- to 60-fold higher risk of developing Burkitt lymphoma compared to the general population, and an estimated 10 to 20% lifetime risk regardless of whether they receive antiretroviral treatment. Interestingly, HIV-associated Burkitt lymphoma behaves differently from most other HIV-related cancers. It tends to appear in people with relatively higher CD4 counts (a measure of immune function) rather than in those with severely depleted immune systems. The risk correlates more strongly with cumulative viral load over time than with the degree of immune suppression at diagnosis.
The likely mechanism involves chronic B-cell stimulation. HIV infection keeps the immune system in a state of ongoing activation, which pushes B cells through repeated rounds of division and antibody gene remodeling. Each round creates another opportunity for AID-mediated errors, including the MYC translocation. EBV is found in 20 to 40% of immunodeficiency-associated cases, suggesting that while the virus contributes, the chronic immune activation from HIV itself is the dominant driver.
Three Subtypes, Three Patterns of Cause
Understanding the causes of Burkitt lymphoma is easier when you see how the three subtypes differ:
- Endemic Burkitt lymphoma primarily affects children in sub-Saharan Africa. It is driven by the combination of early, repeated malaria infections and near-universal EBV exposure. Sub-Saharan West Africa reported 1,324 childhood cases in 2021 alone, and East Africa had the highest incidence rate globally at 0.68 per 100,000 children.
- Sporadic Burkitt lymphoma occurs worldwide at low rates and is the most common form in the U.S. and Europe. EBV plays a smaller role (present in only 10 to 30% of cases), and the triggers are less well understood. The translocation in these cases appears to arise from errors during antibody class switching rather than the earlier gene rearrangement process seen in endemic cases.
- Immunodeficiency-associated Burkitt lymphoma is most closely linked to HIV infection, with the chronic B-cell activation from persistent viral load serving as the primary driver. It can also occur in people on immunosuppressive medications after organ transplantation.
Why It Grows So Fast
Burkitt lymphoma is one of the fastest-growing human cancers, with tumor doubling times as short as 24 to 48 hours. This speed is a direct consequence of MYC’s role. MYC is a master regulator of cell growth. When it’s locked in the “on” position by the translocation, cells skip the normal checkpoints that slow division, and nearly every cell in the tumor is actively dividing at once. Pathologists confirm this by measuring the fraction of dividing cells, which in Burkitt lymphoma approaches 100%.
The rapid growth also explains why the disease responds well to intensive chemotherapy, particularly in children. In high-income countries, more than 80% of children and adolescents survive at least five years with current treatments. The very feature that makes the cancer aggressive, its relentless division, also makes it vulnerable to drugs that target dividing cells.